Keytru­da's cer­vi­cal can­cer da­ta; Ar­cutis’ of­fer­ing; Alaya.bio an­nounces a CAR-T deal

Keytru­da’s pos­i­tive cer­vi­cal can­cer da­ta: Mer­ck said Fri­day that its pow­er­house can­cer drug re­duced the risk of dis­ease pro­gres­sion or death in ad­vanced cer­vi­cal can­cer by 30% in Phase III study re­sults pre­sent­ed at ES­MO. Me­di­an pro­gres­sion-free sur­vival was not reached in ei­ther arm, but PFS at 24 months was 67.8% for the new­ly di­ag­nosed pa­tients who re­ceived Keytru­da on top of chemother­a­py com­pared to 57.3% for those who re­ceived chemother­a­py alone.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER